News
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announcing it’s already announced before.
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...
In 2023, AstraZeneca said it had decided not to build a new $400m drug factory in Britain because of its “discouraging” tax ...
AstraZeneca Plc plans to invest $50 billion in the US before 2030, becoming the latest European pharma company to ratchet up ...
AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...
The move is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry. Read more at ...
AstraZeneca CEO Sir Pascal Soriot explains the reasoning behind its $50 billion expansion of operations across the U.S.
The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback